[
    {
        "symbol": "NKTR",
        "price": 59.92,
        "beta": 1.197,
        "volAvg": 996523,
        "mktCap": 1139594332,
        "lastDiv": 0,
        "range": "6.45-66.92",
        "changes": -5.01,
        "companyName": "Nektar Therapeutics",
        "currency": "USD",
        "cik": "0000906709",
        "isin": "US6402683063",
        "cusip": "640268306",
        "exchange": "NASDAQ Global Select",
        "exchangeShortName": "NASDAQ",
        "industry": "Biotechnology",
        "website": "https://www.nektar.com",
        "description": "Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.",
        "ceo": "Howard W. Robin",
        "sector": "Healthcare",
        "country": "US",
        "fullTimeEmployees": "61",
        "phone": "415 482 5300",
        "address": "455 Mission Bay Boulevard South",
        "city": "San Francisco",
        "state": "CA",
        "zip": "94158",
        "dcfDiff": 116.56468,
        "dcf": -56.03467920110567,
        "image": "https://images.financialmodelingprep.com/symbol/NKTR.png",
        "ipoDate": "1994-05-03",
        "defaultImage": false,
        "isEtf": false,
        "isActivelyTrading": true,
        "isAdr": false,
        "isFund": false
    }
]